Cytyc buys Adeza for $452M

Cytyc Corporation is acquiring Adeza Biomedical Corporation for $452 million. Cytyc makes surgical and diagnostic products targeting women's health and cancer diagnostics, and Adeza manufactures and markets products for women's health. Adeza's primary product is FullTerm, which is used by OB/GYNs to identify women at risk of preterm birth. It also has several products in its pipeline including Gestiva, a drug candidate for the prevention of preterm birth for patients with a history of preterm birth. The company received an approvable letter for the drug back in October.

"The FullTerm Fetal Fibronectin Test offers an excellent complement to our diagnostic products portfolio and will allow us to leverage our formidable sales force which is already calling on obstetricians and gynecologists, as well as commercial labs, in the U.S. and abroad," said Patrick J, Sullivan, Cytyc's chairman, president and CEO.

- see the release on the deal

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.